U.S. District Judge Kenneth Bell ruled in Merck’s (MRK) favor in a safety lawsuit over the company’s Gardasil vaccine, allowing the pharma giant to sidestep over 200 complaints alleging the ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

Merck (MRK) announced the opening of a new, $1B, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site. This expansion of our Durham plant is a ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

LeBron James won’t win his fifth MVP this season. But it can be argued that he deserves a top-five vote. Maybe not top three in what is a two-man race for the award. Is there a forward besides ...

(Reuters) -A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasil, a vaccine to prevent cervical and other fatal cancers. The decision ...

As part of our state championship coverage, the NJ Advance Media boys basketball staff will select a Most Valuable Player and several additional standouts from each game at Rutgers. Check out our ...

Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats. Trump ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...